In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas.
about
PD-L1 expression in human cancers and its association with clinical outcomesTowards tumor immunodiagnosticsCheckpoint Inhibitors and Their Application in Breast CancerTumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune TargetingEpstein-Barr Virus-Associated Gastric Carcinoma and Specific Features of the Accompanying Immune ResponseRelevance of tumor-infiltrating lymphocytes in breast cancerThe anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patientsCurrent Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast CancerBiological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis.PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined SubgroupsPrognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinomaRecent advances in understanding antitumor immunityClinical significance of tumor-infiltrating lymphocytes in breast cancerValidation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validationHigh PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers.Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor.Clinical significance of T cell clonality and expression levels of immune-related genes in endometrial cancer.Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia.The immune microenvironment of breast ductal carcinoma in situ.Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancerPD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer.Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.Modelling the spatial heterogeneity and molecular correlates of lymphocytic infiltration in triple-negative breast cancer.Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic.Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningiomaPrognostic and predictive value of PDL1 expression in breast cancer.PDL1 expression is an independent prognostic factor in localized GIST.Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice.PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy.Monocyte and interferon based therapy for the treatment of ovarian cancer.Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis.Objective measurement and clinical significance of TILs in non-small cell lung cancer.Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma.Immune profiling in human breast cancer using high-sensitivity detection and analysis techniquesAntibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer.Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer.
P2860
Q26738361-9B049553-4FCD-422B-9589-0B286CD56919Q26738691-6C379F07-76DB-4189-92B1-293C1AEFED87Q26745442-DA014DE7-B0C5-4506-ADDC-63960FFC12A7Q26747792-C0DD4800-1922-4E7A-BDD0-1C6AFE263A4BQ26751029-7C4F4DAA-6C6F-4C25-A51A-C9687320AFA0Q26795598-CEF4FE8A-2598-4F6E-B1AF-E3DA2D552067Q26797478-31CB3100-0A93-46A7-B18A-104ADA770F36Q26798074-25D8DE36-4051-4BCD-8DF4-97ADF0F0E574Q27311085-1D5FC484-F12F-4BDE-9C4F-6DDDE090BC8BQ27853205-60EC35C1-DDA5-42A1-8F3F-DF98ECAEFA3DQ27853285-257A5F33-2F02-440D-872C-86A45191EBA9Q28067217-C404CCB8-1E0F-4548-9FBE-8077B96E7403Q28070214-7E03A7AF-1310-4DFC-A7E9-B5051C11CD1AQ28075719-90654326-E35C-4A28-BD7C-BF56916D2AD9Q33566790-B7DA986A-790B-44EB-A314-4BBAB9CFEF42Q33607407-DC311EC0-F431-41AF-8F79-1DE5FA9D04D1Q33671093-35DCB29B-353E-4EF9-96CB-1633726280AEQ33814411-BBFB7493-C03B-4674-86DF-E7905E208E51Q33834968-6D070797-2729-458F-8B82-EC86835EF38FQ34270064-E5C9CE3A-B689-4011-8190-86AE0C4E3B33Q34454922-6351082C-A0F1-4436-A18B-684E2FD877A1Q34522172-D5727DFC-D7D8-40C4-83D3-DB81730BBE88Q35009369-4057B88C-7DCD-43C4-A112-2A388FF92DDEQ35182037-31D2D726-25E3-4062-B4E5-72057929A053Q35251561-64C9BF41-BAC6-4D2F-BDC8-617EF255551CQ35741539-DB517ABF-FECC-4174-AA15-ED1D2D8D6844Q35741710-BAE6F512-6431-417E-9E7A-E23BE0185B12Q35798839-5D964919-C7D8-4228-8939-EB0AFEEBB92AQ35812429-EDD616EC-2977-4E8F-BBD3-FD1999CF4237Q35934137-D4EC58B2-F906-48DD-8C5C-31FD509E8227Q35955369-C11A56E4-A4E7-4612-8581-7888C01D1C9EQ35973378-8B48C085-BD55-471B-A8F5-43E82B2251A0Q36030084-6DAC134C-ABEA-41A4-9BA7-AAB550B5B4CEQ36047422-D3ECA4D3-77EA-479A-A802-B2E4160A44A4Q36072022-C0AA023A-58A4-4BE7-999D-DBEDA9206E96Q36108008-63253078-1A29-486C-896E-B63738E7722CQ36539682-24A3F502-64AF-48BB-9989-677260F2526AQ36545353-C4B85CE2-45DF-45A0-8FD2-EEB4FB6201FFQ36553576-080DE3FB-FFC7-4453-A1D9-2238733E4FCEQ36637292-BE562909-63CD-4E76-8A76-8B6B65D6E67E
P2860
In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
In situ tumor PD-L1 mRNA expre ...... outcome in breast carcinomas.
@en
In situ tumor PD-L1 mRNA expre ...... outcome in breast carcinomas.
@nl
type
label
In situ tumor PD-L1 mRNA expre ...... outcome in breast carcinomas.
@en
In situ tumor PD-L1 mRNA expre ...... outcome in breast carcinomas.
@nl
prefLabel
In situ tumor PD-L1 mRNA expre ...... outcome in breast carcinomas.
@en
In situ tumor PD-L1 mRNA expre ...... outcome in breast carcinomas.
@nl
P2093
P1476
In situ tumor PD-L1 mRNA expre ...... outcome in breast carcinomas.
@en
P2093
Daniel Carvajal
David L Rimm
Hallie Wimberly
Jason Brown
Lajos Pusztai
Vamsidhar Velcheti
P304
P356
10.1158/1078-0432.CCR-13-2702
P407
P577
2014-03-19T00:00:00Z